Tiziana Life Sc Share Price (TILS)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 40.00on 18-10-2019 at 16:30:00
Change 0.00 0.00%
Buy 45.00
Sell 35.00
Buy / Sell TILS Shares
Sponsored Financial Content
Last Trade: Sell 211 at 35.30p
Day's Volume: 211
Last Close: 40.00p
Open: 40.00p
Day's Range 40.00p - 40.00p
52wk Range: 35.00p - 100.00p
Market Capitalisation: £55m
VWAP: 0.00p
Shares in Issue: 136m

Recent Trades History Tiziana Life Sc (TILS)

Buy/Sell Volume Trade Prc Trade Type Trade Time
08:03:29 - 18-Oct-19
15:26:39 - 17-Oct-19
15:11:08 - 17-Oct-19
15:02:48 - 17-Oct-19
11:38:45 - 17-Oct-19
11:02:59 - 17-Oct-19
10:10:17 - 17-Oct-19
10:02:57 - 17-Oct-19
09:48:50 - 17-Oct-19
09:25:38 - 17-Oct-19

Share Price History for Tiziana Life Sc

Time period:
Date Open High Low Close
17th Oct 2019 (Thu)40.0040.0035.0040.00
16th Oct 2019 (Wed)40.0040.0040.0040.00
15th Oct 2019 (Tue)42.5042.5040.0042.50
14th Oct 2019 (Mon)45.0045.0042.5042.50
11th Oct 2019 (Fri)40.0045.0040.0045.00
10th Oct 2019 (Thu)44.5045.0043.5046.00
9th Oct 2019 (Wed)45.0046.0040.0046.00
8th Oct 2019 (Tue)45.0045.0045.0045.00
7th Oct 2019 (Mon)45.5045.5041.0045.00
4th Oct 2019 (Fri)50.0050.0050.0050.00
3rd Oct 2019 (Thu)50.0050.0050.0050.00
2nd Oct 2019 (Wed)50.0050.0050.0050.00
1st Oct 2019 (Tue)50.0050.0050.0050.00
30th Sep 2019 (Mon)50.0050.0045.0050.00
27th Sep 2019 (Fri)51.5051.5048.0051.50
26th Sep 2019 (Thu)51.5051.5048.0051.50
25th Sep 2019 (Wed)51.5051.5051.5051.50
24th Sep 2019 (Tue)54.0054.0050.0051.50
23rd Sep 2019 (Mon)55.0055.0054.0054.00
20th Sep 2019 (Fri)57.5057.5055.0055.00

News about Tiziana Life Sc (TILS)

Tiziana Life Sciences gets green light from FDA for US clinical trial

News - Monday, September 16, 2019

Cancer and inflammatory diseases focused Tiziana Life Sciences said the US Food and Drug Administration had allowed the initiation of a clinical trial of a treatment for autoimmune and inflammatory diseases. The Phase I clinical trial of the Foralumab treatment would be conducted in healthy volunteers using a novel oral enteric-coated capsule formulation in collaboration with the Brigham and Women's Hospital, Harvard Medical School, Boston. 'This is the first clinical trial in which Foralumab will be administered orally to healthy subjects,' the company said. 'Our objective is to develop orally administered Foralumab for treatment of autoimmune and inflammatory diseases.' Story provided by StockMarketWire.com. ...

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered